Medigene AG Stock
Medigene AG Stock
We see a rather positive sentiment for Medigene AG with 7 Buy predictions and 1 Sell predictions.
As a result the target price of €8.00 shows a very positive potential of 68.955% compared to the current price of €4.74 for Medigene AG.
For the coming years our community has positive and negative things to say abot the Medigene AG stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "General Risks" there were negative voices in the community.
Pros and Cons of Medigene AG in the next few years
Pros
Cons
Performance of Medigene AG vs. its peers
Security | Change (%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Medigene AG | -1.150% | 3.724% | 28.320% | -21.671% | 33.946% | -68.007% | -37.118% |
B.R.A.I.N. Biotechnology Research and Information Network AG | -0.450% | -6.667% | -2.032% | -12.412% | -4.194% | -68.147% | - |
Affimed N.V. | -5.470% | -5.938% | -0.852% | 105.134% | 10.119% | - | - |
Formycon AG | -0.320% | -0.639% | -3.715% | 93.168% | 17.358% | 90.798% | 226.167% |
Comments
Other discussions about Medigene AG Stock
Trading Medigene AG
Trading Medigene AG
News

Medigene AG: Medigene provides Q3 2020 update
Business news for the stock market
Planegg/Martinsried (12.11.2020) - Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development

Medigene AG: Oral and poster presentations on Medigene's clinical research at ASH conference
Business news for the stock market
Planegg/Martinsried (05.11.2020) - 5 November 2020. Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing

Medigene AG: Medigene and Cytovant enter into service agreement for DC vaccine manufacturing process development
Planegg/Martinsried (19.10.2020) - Medigene AG (MDG1, Frankfurt, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies for the

Medigene AG: Three Medigene poster presentations at SITC Annual Meeting
Planegg/Martinsried (15.10.2020) - Scientists of Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell

Medigene AG: Medigene expands patent protection of its technologies
Planegg/Martinsried (06.10.2020) - Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, has

Medigene AG: Medigene participates at upcoming virtual conferences
Martinsried/ Munich (28.09.2020) - Medigene AG (FSE: MDG1, Prime Standard) today announces its participation at the following upcoming scientific and investor conferences. Please note that

Medigene AG: Strategic measures including restructuring with extension of cash runway and improved EBITDA
Business news for the stock market
Planegg/Martinsried (22.09.2020) - 22 September 2020. Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing

Medigene provides Q2 update and 6M report 2020
Conference call on 7 August 2020 at 2pm CET (Frankfurt) / 8am EDT (New York)
Business news for the stock market
Martinsried/ Munich (07.08.2020) - Medigene AG (Medigene, FSE: MDG1, Prime

Medigene AG: Medigene expands patent protection of its technologies in key markets, the USA and Europe
Planegg/Martinsried (13.01.2021) - Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, was

Medigene AG: Participation at upcoming virtual conferences
Planegg/Martinsried (21.12.2020) - 21 December 2020. Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell

Medigene AG: Dr. Anthony Man appointed to Supervisory Board
Planegg/Martinsried (16.12.2020) - The Executive Management Board and the Supervisory Board of Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company

Medigene AG: PRAME expression and HLA genotype screening in AML and MDS patients
Poster at ASH Annual Meeting 2020, 5-8 December 2020
Planegg/Martinsried (07.12.2020/16:00) - Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company f

Medigene AG: Detailed analysis from Medigene's completed Phase I/II DC vaccine in AML patients presented orally at ASH 2020
Planegg/Martinsried (07.12.2020) - Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, is